Knockdown of REGγ inhibits the proliferation and migration and promotes the apoptosis of multiple myeloma cells by downregulating NF-κB signal pathway

References

• Fairfield H, Falank C, Avery L, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364:32–51. doi: 10.1111/nyas.13038
   PubMed Web of Science ®Google Scholar
• Bianchi G, Kumar S, Ghobrial IM, et al. Cell trafficking in multiple myeloma. Open J Hematol. 2011;48:S8–S.
   Google Scholar
• Dispenzieri A, Kyle RA. Multiple myeloma: clinical features and indications for therapy. Best Pract Res Clin Haematol. 2005;18:553–568. doi: 10.1016/j.beha.2005.01.008
   PubMed Web of Science ®Google Scholar
• Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732–741. doi: 10.1016/j.exphem.2015.04.010
   PubMed Web of Science ®Google Scholar
• Lambert KE, Huang H, Mythreye K, et al. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell. 2011;22:1463–1472. doi: 10.1091/mbc.e10-11-0877
   PubMed Web of Science ®Google Scholar
• Zhang M, Gan L, Ren GS. REGγ is a strong candidate for the regulation of cell cycle, proliferation and the invasion by poorly differentiated thyroid carcinoma cells. Braz J Med Biol Res. 2012;45:459. doi: 10.1590/S0100-879X2012007500035
   PubMed Web of Science ®Google Scholar
• Jing H, Long C, Yu Z, et al. REGγ is associated with multiple oncogenic pathways in human cancers. BMC Cancer. 2012;12:3971.
   Web of Science ®Google Scholar
• Mao I, Liu J, Li X, et al. REGgamma, a proteasome activator and beyond? Cell Mol Life Sci. 2008;65:3971–3980. Epub 2008/08/06. doi: 10.1007/s00018-008-8291-z
   PubMedGoogle Scholar
• Chai F, Liang Y, Bi J, et al. High expression of REGγ is associated with metastasis and poor prognosis of patients with breast cancer. Int J Clin Exp Pathol. 2014;7:7834.
   PubMedGoogle Scholar
• Tian M, Xiaoyi W, Xiaotao L, et al. Proteasomes reactivator REG gamma enchances oncogenicity of MDA-MB-231 cell line via promoting cell proliferation and inhibiting apoptosis. Cell Mol Biol. 2009;55(Suppl):OL1121–OL1131.
   PubMedGoogle Scholar
• Chai F, Liang Y, Bi J, et al. REGgamma regulates ERalpha degradation via ubiquitin-proteasome pathway in breast cancer. Biochem Biophys Res Commun. 2015;456:534–540. Epub 2014/12/10. doi: 10.1016/j.bbrc.2014.11.124
   PubMed Web of Science ®Google Scholar
• Ali A, Wang Z, Fu J, et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat Commun. 2013;4:2667. Epub 2013/10/26. doi: 10.1038/ncomms3667
   PubMed Web of Science ®Google Scholar
• D’Ignazio L, Batie M, Rocha S, et al. Hypoxia and inflammation in cancer, focus on HIF and NF-kappaB. Biomedicines. 2017;5:21–44. Epub 2017/05/26. doi: 10.3390/biomedicines5020021
   Web of Science ®Google Scholar
• Matthews GM, de Matos Simoes R, Dhimolea E, et al. NF-kappaB dysregulation in multiple myeloma. Semin Cancer Biol. 2016;39:68–76. Epub 2016/08/22. doi: 10.1016/j.semcancer.2016.08.005
   PubMed Web of Science ®Google Scholar
• Xiang Y, Remilywood ER, Oliveira V, et al. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2011;10:M110.005520. doi: 10.1074/mcp.M110.005520
   PubMed Web of Science ®Google Scholar
• Chen WM. [The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision): interpretation of the treatment of relapsing and refractory multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2016;55:93–94.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta C(T))method. Methods. 2001;Dec;25(4):402–408. doi: 10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Chai F, Liang Y, Bi J, et al. High expression of REGgamma is associated with metastasis and poor prognosis of patients with breast cancer. Int J Clin Exp Pathol. 2014;7:7834–7843. Epub 2015/01/01.
   PubMedGoogle Scholar
• Qin Q, Guo FC, Luo ST, et al. [REGgamma promotes malignant behaviors of lung cancer cells]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45:304–308. Epub 2014/04/23.
   PubMedGoogle Scholar
• Chen D, Yang X, Huang L, et al. The expression and clinical significance of PA28 gamma in colorectal cancer. J Investig Med. 2013;61:1192–1196. Epub 2013/10/12. doi: 10.2310/JIM.0000000000000001
   PubMed Web of Science ®Google Scholar
• Wang H, Bao W, Jiang F, et al. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett. 2015;360:269–279. Epub 2015/02/24. doi: 10.1016/j.canlet.2015.02.028
   PubMed Web of Science ®Google Scholar
• Gilmore TD. Multiple myeloma: lusting for NF-κB. Cancer Cell. 2007;12:95–97. doi: 10.1016/j.ccr.2007.07.010
   PubMed Web of Science ®Google Scholar
• Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Ann Rev Biophys. 2013;42:443–468. doi: 10.1146/annurev-biophys-083012-130338
   PubMed Web of Science ®Google Scholar
• Xu J, Sun HY, Xiao FJ, et al. SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma cells through modulation of NF-kappaB signaling. Biochem Biophys Res Commun. 2015;460:409–415. Epub 2015/03/21. doi: 10.1016/j.bbrc.2015.03.047
   PubMed Web of Science ®Google Scholar
• Li Z, Yang Z, Peng X, et al. Nuclear factor-kappaB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma. Mol Med Rep. 2014;10:832–838. Epub 2014/06/04. doi: 10.3892/mmr.2014.2285
   PubMed Web of Science ®Google Scholar
• Hideshima T, Neri P, Tassone P, et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006;12:5887–5894. Epub 2006/10/06. doi: 10.1158/1078-0432.CCR-05-2501
   PubMed Web of Science ®Google Scholar
• Xu J, Lei Z, Lei J, et al. The REGγ-proteasome forms a regulatory circuit with IκBϵ and NFκB in experimental colitis. Nat Commun. 2016;7:10761. doi: 10.1038/ncomms10761
   PubMed Web of Science ®Google Scholar
• Choi YA, Lim HK, Kim JR, et al. Group IB secretory phospholipase A2 promotes matrix metalloproteinase-2-mediated cell migration via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem. 2004;279:36579–6585. Epub 2004/06/29. doi: 10.1074/jbc.M314235200
   PubMed Web of Science ®Google Scholar
• Bolkun L, Lemancewicz D, Sobolewski K, et al. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment. Adv Med Sci. 2013;58:118–125. Epub 2013/01/22. doi: 10.2478/v10039-012-0048-0
   PubMed Web of Science ®Google Scholar
• Urbaniak-Kujda D, Kapelko-Slowik K, Prajs I, et al. Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma. Hematology. 2016;21:26–33. Epub 2015/08/14. doi: 10.1179/1607845415Y.0000000043
   PubMed Web of Science ®Google Scholar
• Kunze D, Kraemer K, Erdmann K, et al. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol. 2012;41:1271–1277. Epub 2012/07/17.
   PubMed Web of Science ®Google Scholar
• Takeda T, Tsubaki M, Kino T, et al. Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor kappaB pathway. Int J Oncol. 2016;48:2704–2712. Epub 2016/04/02. doi: 10.3892/ijo.2016.3470
   PubMed Web of Science ®Google Scholar
• Chen G, Han K, Xu X, et al. An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway. Br J Cancer. 2014;110:63–70. Epub 2013/11/16. doi: 10.1038/bjc.2013.711
   PubMed Web of Science ®Google Scholar